CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 103,800 shares, a growth of 91.5% from the February 29th total of 54,200 shares. Based on an average trading volume of 394,600 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.3% of the shares of the stock are sold short.

Hedge Funds Weigh In On CNS Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Smith Anglin Financial LLC bought a new position in shares of CNS Pharmaceuticals during the fourth quarter valued at approximately $64,000. Armistice Capital LLC acquired a new stake in CNS Pharmaceuticals in the fourth quarter valued at approximately $320,000. Renaissance Technologies LLC boosted its stake in CNS Pharmaceuticals by 242.9% in the first quarter. Renaissance Technologies LLC now owns 506,532 shares of the company’s stock valued at $173,000 after acquiring an additional 358,832 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in CNS Pharmaceuticals by 689.3% in the first quarter. Bank of New York Mellon Corp now owns 234,892 shares of the company’s stock valued at $80,000 after acquiring an additional 205,134 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in CNS Pharmaceuticals by 145.6% in the fourth quarter. Vanguard Group Inc. now owns 58,369 shares of the company’s stock valued at $74,000 after acquiring an additional 34,604 shares in the last quarter. 14.02% of the stock is currently owned by institutional investors.

CNS Pharmaceuticals Stock Performance

CNS Pharmaceuticals stock traded down $0.01 during midday trading on Friday, reaching $0.36. The stock had a trading volume of 182,004 shares, compared to its average volume of 310,947. CNS Pharmaceuticals has a 52-week low of $0.23 and a 52-week high of $4.40. The company has a fifty day moving average of $0.35 and a 200 day moving average of $1.14.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.